Looking at the universe of stocks we cover at Dividend Channel, on 2/12/14, Neenah Paper Inc (NP - Get Report) will trade ex-dividend, for its quarterly dividend of $0.24, payable on 3/4/14. As a percentage of NP's recent stock price of $43.52, this dividend works out to approximately 0.55%, so look for shares of Neenah Paper Inc to trade 0.55% lower — all else being equal — when NP shares open for trading on 2/12/14.Below is a dividend history chart for NP, showing historical dividends prior to the most recent $0.24 declared by Neenah Paper Inc: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from NP is likely to continue, and whether the current estimated yield of 2.21% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of NP shares, versus its 200 day moving average: Looking at the chart above, NP's low point in its 52 week range is $27.44 per share, with $44.82 as the 52 week high point — that compares with a last trade of $43.52. According to the ETF Finder at ETF Channel, NP makes up 1.72% of the S&P SmallCap Materials Portfolio ETF ( PSCM) which is trading relatively unchanged on the day Monday. In Monday trading, Neenah Paper Inc shares are currently up about 0.2% on the day.
More from Stocks
Top 5 Stock Winners in Dow Jones Industrial Average This Week
The Dow Jones Industrial Average finished Friday above 28000 for the first time ever. Here are the top 5 winning stocks in the Dow from this week.
Bottom 3 Loser Stocks in Dow Jones Industrial Average This Week
These 3 stocks did not help the Dow Jones Industrial Average finish Friday above 28000. Here are the bottom 3 losing stocks from this week.
Why Stock Charts Are a More Valuable Tool Than Ever
What I have found is that the real value of charts is as a trade management tool.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.